Kairos Pharma (KAPA) Interest Expenses (2023 - 2025)

Kairos Pharma (KAPA) has 3 years of Interest Expenses data on file, last reported at $813000.0 in Q4 2025.

• Quarterly Interest Expenses rose 28.03% year-over-year to $813000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $813000.0 (up 22.07% YoY) and the FY2025 annual result came in at $3.0 million, up 257.79% from the prior year.
• Interest Expenses climbed to $813000.0 in Q4 2025, from $192000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $813000.0 in Q4 2025 to a low of $3000.0 in Q4 2023.
• A 3-year average of $279000.0 and a median of $192000.0 in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses jumped 21066.67% — and 2025, when it climbed 28.03%.
• Tracing KAPA's Interest Expenses over 3 years: stood at $3000.0 in 2023, then jumped by 21066.67% to $635000.0 in 2024, then gained by 28.03% to $813000.0 in 2025.
• The last three Interest Expenses figures came in at $813000.0 (Q4 2025), $192000.0 (Q2 2025), and $288000.0 (Q1 2025), per Business Quant data.